Drug Trial Radar · NCT05676931
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Feb 21, 2023
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- Arcus Biosciences, Inc.
- First posted
- Jan 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
Conditions
- Advanced Non-Small Cell Lung Cancer
Interventions
DomvanalimabDrug
Administered as specified in the treatment arm
QuemliclustatDrug
Administered as specified in the treatment arm
ZimberelimabDrug
Administered as specified in the treatment arm
DocetaxelDrug
Administered as specified in the treatment arm
Platinum-Based DoubletDrug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)Time frame: Up to 58 months
- The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to 58 months
Locations
53 sites in 10 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham (UAB)
Birmingham, Alabama
University of California San Diego (UCSD)
La Jolla, California
Memorial Cancer Institute at Memorial Regional Hospital
Hollywood, Florida
Hematology Oncology Associates Of The Treasure Coast
Port Saint Lucie, Florida
Florida Cancer Specialists (Administration and Drug Shipment)
The Villages, Florida
Northwestern Memorial Hospital
Chicago, Illinois
Ochsner Clinic Foundation
Jefferson, Louisiana
Henry Ford Hospital
Detroit, Michigan
Virginia Cancer Specialists, PC
Fairfax, Virginia
Medical Oncology Associated, PS (dba Summit Cancer Centers)
Spokane, Washington
The Border Cancer Hospital
Albury, New South Wales, Australia
Pindara Private Hospital
Benowa, Queensland, Australia
Cancer Research SA Pty Ltd
Adelaide, South Australia, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
CHU Bordeaux Centre Francois Magendie Hôpital du Haut Lévèque
Bordeaux, France
Hospices Civils de Lyon Centre Hospitalier Lyon Sud
Lyon, France
Institut De Cancerologie Strasbourg Europe ICANS
Strasboug, France
Hopital FOCH
Suresnes, France
LTD High Technology Hospital Medcenter
Batumi, Georgia
Caucasus Medical Center
Tbilisi, Georgia
Israel Georgian Medical Research Clinic Healthycore
Tbilisi, Georgia
JSC K. Eristavi National Center of Experimental and Clinical Surgery
Tbilisi, Georgia
Ltd Pineo Medical Ecosystem
Tbilisi, Georgia
Istituto Romagnolo per lo Studio dei Tumori-Dino Amadori - IRST
Meldola, Italy
stituto Nazionale per lo Studio e la Cura dei Tumori
Milan, Italy
Istituto Oncologico Veneto IRCCS
Padova, Italy
Azienda Sanitaria Territoriale Pesaro Urbino (AST PU)
Pesaro, Italy
Fondazione IRCCS Istituto Nazionale dei tumori di Milano
Rome, Italy
Szpitale Pomorskie sp. z o.o
Gdynia, Poland
Uniwersyteckie Centrum Kliniczne, im. prof. K. Gibińskiego
Katowice, Poland
Medpolonia Sp. Z.o.o.
Poznan, Poland
Centrum Onkologii - Instytut im. Marii Sk?odowskiej-Curie
Warsaw, Poland
Samsung Changwon Hospital
Changwon-Si, South Korea
Chungbuk National University Hospital
Cheongju-si, South Korea
Chonam National University Hwasun Hospital
Hwasun-gun, South Korea
Korea University Guro Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitari Mutua Terrassa
Barcelona, Spain
UOMI Cancer Centre
Barcelona, Spain
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.